Predictions are only orientative, and often approximate, so decisions should be taken at the discretion of the attending physician. In particular, clinical trials have included only patients with Ki67% up to 10%. Therefore, predictions based on proliferation indices greater than 10% may be subject to more uncertainty, and be overestimated.